These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22297839)

  • 1. Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
    Chen Y; Yang Y; Wang C; Shi Y
    J Surg Oncol; 2012 Aug; 106(2):162-8. PubMed ID: 22297839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival.
    Chou YS; Liu CY; Chen WM; Chen TH; Chen PC; Wu HT; Chiou HJ; Shiau CY; Wu YC; Liu CL; Chao TC; Tzeng CH; Yen CC
    J Surg Oncol; 2012 Aug; 106(2):155-61. PubMed ID: 22297812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
    Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
    Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
    Kataoka K; Tanaka K; Mizusawa J; Kimura A; Hiraga H; Kawai A; Matsunobu T; Matsumine A; Araki N; Oda Y; Fukuda H; Iwamoto Y;
    Jpn J Clin Oncol; 2014 Aug; 44(8):765-9. PubMed ID: 24916336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
    DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhao J; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
    Eilber FC; Eilber FR; Eckardt J; Rosen G; Riedel E; Maki RG; Brennan MF; Singer S
    Ann Surg; 2004 Oct; 240(4):686-95; discussion 695-7. PubMed ID: 15383796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
    Ogura K; Goto T; Imanishi J; Shinoda Y; Okuma T; Tsuda Y; Kobayashi H; Akiyama T; Hirata M; Yamamoto A; Kawano H
    Int J Clin Oncol; 2013 Feb; 18(1):170-6. PubMed ID: 22179493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
    Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
    BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
    Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
    Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
    O'Sullivan B; Bell RS
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):915-6. PubMed ID: 12829123
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
    Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
    Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
    Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.